Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Axitinib and Avelumab in High-Risk Localized RCC (NEOAVAX)
NCT03341845Phase 2Unknown
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2018
- Primary completion
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab, axitinib in clear cell renal cell carcinoma (ccRCC), sponsored by Netherlands Cancer Institute. Status: unknown.
02
Drugs
avelumabaxitinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT03341845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03341845.